76 results
424B3
SEEL
Seelos Therapeutics Inc
15 Mar 24
Prospectus supplement
4:15pm
arrangement or understanding, other than compensation arrangements in the ordinary course of business.
Director Independence
Our Board has determined … that each of Mr. Pascoe and Drs. Lian and Dalesandro met the definitions of independence under the Nasdaq Rules and Section 10A-3 of the Exchange Act
8-K
EX-1.1
SEEL
Seelos Therapeutics Inc
30 Nov 23
Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering
4:59pm
Palo Alto, CA 94304
Attention: Jeff Hartlin
Email: jeffhartlin@paulhastings.com
8.2 Research Analyst Independence. The Company acknowledges
8-K
EX-1.1
q9k3f aau1
12 May 22
Entry into a Material Definitive Agreement
8:31am
8-K
EX-1.1
c5jfughq02 idn
21 May 21
Seelos Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock
12:00am
8-K
EX-1.1
6wyyyp
12 Mar 20
Seelos Therapeutics Announces Pricing of $4.5 Million Public Offering of Common Stock
5:24pm
424B4
jz8foij7vl70xog4ut
11 Feb 20
Prospectus supplement with pricing info
5:14pm
8-K
EX-1.1
4r8k3
11 Feb 20
Seelos Therapeutics Announces Pricing of $5 Million Public Offering of Common Stock
6:08am